Target intelligence / Profile preview

X-ray repair cross-complementing protein 6 (XRCC6)

Target
XRCC6
Molecular classification
DNA repair protein, Enzyme, DNA-binding protein, Component of non-homologous end joining machinery, Cytosolic DNA sensor
01

Overview

X-ray repair cross-complementing protein 6 (XRCC6), also known as Ku70, is a critical component of the non-homologous end joining (NHEJ) pathway for DNA double-strand break repair. It forms a heterodimer with Ku80 (XRCC5), binding to DNA ends with high affinity and shielding them from nucleolytic degradation, while recruiting additional repair factors including DNA-dependent protein kinase catalytic subunit (DNA-PKcs), XRCC4, and Ligase IV[1][3][4][6]. Ku70 is also essential for V(D)J recombination in lymphocyte development, telomere maintenance, and modulation of apoptosis via interaction with proteins such as Bax and p53. Beyond nuclear functions, Ku70 acts as a cytosolic DNA sensor, activating innate immune responses, and serves as a cell-surface receptor in bacterial internalization. Mutation or altered expression of XRCC6 is implicated in cancer, neurodegeneration, and immune disorders. As a therapeutic target, its primary relevance is for modulating DNA repair in cancer therapy and as a marker for disease susceptibility and treatment response[3][5].

Other names
Ku705'-dRP lyase Ku70DNA repair protein XRCC6ATP-dependent DNA helicase 2 subunit 1Lupus Ku autoantigen protein p70Thyroid-lupus autoantigenCTC75CTCBFG22P1ML8TLAA70 kDa subunit of Ku antigen5'-deoxyribose-5-phosphate lyase Ku70
02

Mechanism of action

Inhibition of non-homologous end joining by targeting components of DNA-PK (including Ku70/Ku80/DNA-PKcs complex) reduces DNA repair capacity and sensitizes cells to DNA damage Ku70 may be targeted to sensitize tumor cells to radiation or DNA-damaging agents Modulation of immune sensing pathways (cytosolic DNA sensing via Ku70)

03

Biological functions

DNA double-strand break repairNon-homologous end joining (NHEJ)Maintenance of genomic stabilityTelomere maintenanceRegulation of apoptosisTranscriptional modulationInnate immune response
04

Disease associations

Cancer (breast, lung, head and neck, oral, among others)Neurodegenerative diseaseImmune system diseases (e.g., lupus, thyroid-lupus autoantigen, autoimmune syndromes)Radiation sensitivityOther disorders associated with genomic instability
05

Safety considerations

Systemic inhibition could impair normal tissue DNA repair, increasing risk of genome instability, mutagenesis, and secondary malignanciesPotential for neurotoxicity, as Ku70 is required for nervous system development and radioprotection[5]Risk of immune modulation due to its role in DNA sensing and apoptosis regulation
06

Interacting drugs

Currently, no approved targeted drugs that directly inhibit or modulate XRCC6/Ku70 in clinical use; it is a potential, not an established, direct drug target[3].

2 more in the full profile.

07

Biomarkers

XRCC6/Ku70 expression level can serve as a biomarker for DNA repair capacity and radiosensitivity in cancer and possibly for predicting response to radiation or DNA-damaging chemotherapy[5].Genetic polymorphisms in XRCC6 associated with cancer risk[3].Autoantibodies against Ku70/Ku80 in autoimmune diseases (e.g., lupus)

Beyond the preview

Go deeper on X-ray repair cross-complementing protein 6 (XRCC6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on X-ray repair cross-complementing protein 6 (XRCC6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call